Understood regarding completion of the trial, my point was a lot of discussion has occured around the high drop-out rate of the Afrezza arms in previous studies, and how the new inhaler would reduce the drop-out rate.

I am hoping that the higher than expected drop-out rate, which is assumed higher than previous trials, was due to the requirement to use the E-diary, which according to anecdotal evidence, went off like an alarm clock multiple times per day until the necessary data was entered.

Either case, good conference call, trials are progressing as expected, and for the first time in recent memory, a timeline that management had laid out prior, is spot on.

Best,

Bob